109 related articles for article (PubMed ID: 8764564)
1. In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine.
Hsieh-Ma ST; Shi T; Reeder J; Ring DB
Clin Immunol Immunopathol; 1996 Aug; 80(2):185-93. PubMed ID: 8764564
[TBL] [Abstract][Full Text] [Related]
2. Murine bispecific antibody 1A10 directed to human transferrin receptor and a 42-kDa tumor-associated glycoprotein.
Shi T; Hsieh-Ma ST; Reeder J; Ring DB
Clin Immunol Immunopathol; 1996 Feb; 78(2):188-95. PubMed ID: 8625561
[TBL] [Abstract][Full Text] [Related]
3. Antigen forks: bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens.
Ring DB; Hsieh-Ma ST; Shi T; Reeder J
Cancer Immunol Immunother; 1994 Jul; 39(1):41-8. PubMed ID: 8044825
[TBL] [Abstract][Full Text] [Related]
4. Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor.
Amoroso AR; Clark JI; Litwin S; Hsieh-Ma S; Shi T; Alpaugh RK; Adams GP; Wolf EJ; Ring DB; Weiner LM
Cancer Res; 1996 Jan; 56(1):113-20. PubMed ID: 8548750
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor.
Kemp JD; Smith KM; Kanner LJ; Gomez F; Thorson JA; Naumann PW
Blood; 1990 Sep; 76(5):991-5. PubMed ID: 2393721
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a threshold model of iron deprivation toxicity.
Kemp JD; Thorson JA; Stewart BC; Naumann PW
Cancer Res; 1992 Aug; 52(15):4144-8. PubMed ID: 1638529
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor.
Kemp JD; Cardillo T; Stewart BC; Kehrberg E; Weiner G; Hedlund B; Naumann PW
Cancer Res; 1995 Sep; 55(17):3817-24. PubMed ID: 7641199
[TBL] [Abstract][Full Text] [Related]
8. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects.
White S; Taetle R; Seligman PA; Rutherford M; Trowbridge IS
Cancer Res; 1990 Oct; 50(19):6295-301. PubMed ID: 2400993
[TBL] [Abstract][Full Text] [Related]
9. A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines.
Crews JR; Maier LA; Yu YH; Hester S; O'Briant K; Leslie DS; DeSombre K; George SL; Boyer CM; Argon Y
Int J Cancer; 1992 Jul; 51(5):772-9. PubMed ID: 1351885
[TBL] [Abstract][Full Text] [Related]
10. Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro.
Kovar J; Naumann PW; Stewart BC; Kemp JD
Pathobiology; 1995; 63(2):65-70. PubMed ID: 8554701
[TBL] [Abstract][Full Text] [Related]
11. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
[TBL] [Abstract][Full Text] [Related]
12. Anti-idiotype x anti-LFA-1 bispecific antibodies inhibit metastasis of B cell lymphoma.
Cohen S; Haimovich J; Hollander N
J Immunol; 2003 Mar; 170(5):2695-701. PubMed ID: 12594299
[TBL] [Abstract][Full Text] [Related]
13. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor.
Kemp JD
Histol Histopathol; 1997 Jan; 12(1):291-6. PubMed ID: 9046063
[TBL] [Abstract][Full Text] [Related]
14. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
Dreier T; Baeuerle PA; Fichtner I; Grün M; Schlereth B; Lorenczewski G; Kufer P; Lutterbüse R; Riethmüller G; Gjorstrup P; Bargou RC
J Immunol; 2003 Apr; 170(8):4397-402. PubMed ID: 12682277
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte lines under iron-depriving conditions: transferrin receptor expression related to various growth responses.
Kovár J; Seligman P; Gelfand EW
Immunol Lett; 1994 Oct; 42(3):123-7. PubMed ID: 7890311
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of hematopoietic progenitor colony growth by a monoclonal antibody against the transferrin receptor: comparison of unconjugated antibody with an immunotoxin containing recombinant ricin A chain.
Shannon KM; Ring DB; Houston LL; Schaffner V; Naylor J; Torkildson JC; Reid SA; Larrick J
Int J Cell Cloning; 1990 Sep; 8(5):368-76. PubMed ID: 2230286
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic drugs that interfere with iron metabolism in cancer cells.
Head JF; Wang F; Elliott RL
Adv Enzyme Regul; 1997; 37():147-69. PubMed ID: 9381969
[TBL] [Abstract][Full Text] [Related]
18. Selection of tumor-specific internalizing human antibodies from phage libraries.
Poul MA; Becerril B; Nielsen UB; Morisson P; Marks JD
J Mol Biol; 2000 Sep; 301(5):1149-61. PubMed ID: 10966812
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo.
Jiang XP; Wang F; Yang DC; Elliott RL; Head JF
Anticancer Res; 2002; 22(5):2685-92. PubMed ID: 12529982
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth of the lymphocyte lines by deferoxamine under various iron-supply conditions.
Kovár J; Seligman P; Gelfand EW
Folia Biol (Praha); 1993; 39(1):29-39. PubMed ID: 8348983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
